NCI ID NCI-2019-03600
NCT ID NCT04208490
CTEP ID WF-1805CD
Primary Purpose HEALTH_SERVICES_RESEARCH
Anatomic Sites Multiple
Minimum Age 18 Years
Maximum Age 999 Years
Gender BOTH
Lead Org Wake Forest NCORP Research Base
Principal Investigator Kathryn E. Weaver
NCI Site View on ClinicalTrials.gov

Implementation and Effectiveness of HN-STAR in Managing the Health of Head and Neck Squamous Cell Cancer Survivors

This trial studies how a computer program, the Head and Neck Survivorship Tool: Assessment and Recommendations (HN-STAR) works in helping health care providers care for survivors of head and neck squamous cell cancer. HN-STAR is a type of survivorship tool that survivors and their health care providers may use together to better manage the survivors' health.

Eligibility

Inclusion Criterea

  • NCORP PRACTICE: Willing to incorporate the web-based HN-STAR into their clinical practice
  • NCORP PRACTICE: Treated >= 12 newly diagnosed cases of head and neck cancer patients within the last 12 months (or the last 12 months of available data)
  • NCORP PRACTICE: Can identify at least one designated clinician who is willing to be trained on and use HN-STAR or conduct usual care for enrolled survivors
  • SURVIVOR: Diagnosis of primary or locoregionally recurrent head and neck squamous cell carcinoma, specifically oral cavity, larynx, any part of pharynx and unknown squamous cell carcinoma primary
  • SURVIVOR: Completed chemotherapy and/or radiation therapy (with or without surgery) with curative intent for head and neck squamous cell carcinoma =< 24 months prior to designated clinician visit
  • SURVIVOR: Deemed free of disease at last assessment (per scan or clinical assessment)
  • SURVIVOR: Cognitively and physically able to complete study survey per local NCORP site staff discretion
  • SURVIVOR: Scheduled for a clinic visit with a provider who has agreed to participate in this study
  • SURVIVOR: Willing to complete study assessments after the designated clinic visit either 1) remotely (via smartphone, tablet, or computer) or 2) at the clinic on a clinic tablet or computer
  • DESIGNATED CLINICIAN: Doctor of Medicine (MD), Doctor of Osteopathic Medicine (DO), nurse practitioner (NP), or physician's assistant (PA)
  • DESIGNATED CLINICIAN: Able to speak and read English, because the HN-STAR tool is only available in English at this time
  • DESIGNATED CLINICIAN: Routinely provides care for cancer patients or survivors
  • DESIGNATED CLINICIAN: Willing to complete study-specific trainings and incorporate HN-STAR or provide usual care in a routine follow-up care visit
  • STAKEHOLDERS: Member of the practice clinical or administrative team who is involved in the oversight of the delivery of head and neck cancer survivorship care or who would make decisions about implementing head and neck survivorship tools such as HN-STAR. This could include clinic administrators, nurse navigators, key clinical team members, program directors, information technology specialists, and other staff (e.g., service line or nursing leaders)
  • STAKEHOLDERS: Employed for at least one month at the practice
  • STAKEHOLDERS: Able to speak and read English, because the HN-STAR tool is only available in English at this time
  • PRIMARY CARE PROVIDER: Provides primary care (general preventive care) to a survivor enrolled in the HN-STAR study
  • PRIMARY CARE PROVIDER: MD, DO, NP, or PA

Exclusion Criterea

  • SURVIVOR: In active cancer treatment (including hormone therapy) for any other cancer excluding local therapy for non-melanoma skin cancer
  • SURVIVOR: Head and neck tumor histology of lymphoma, adenocarcinoma or melanoma
  • SURVIVOR: Recurrent, persistent, or progressive disease at last assessment (per scan or clinical assessment)
  • SURVIVOR: Does not speak or read English, because the HN-STAR tool is only available in English at this time
  • SURVIVOR: Received only surgery as treatment for head and neck cancer
  • SURVIVOR: Current, planned enrollment, or in follow-up on another interventional symptom management study protocol, as per patient self-report or research staff members’ knowledge at the time of consent. Concurrent participation in treatment or imaging studies is allowed
  • STAKEHOLDERS: Is the designated clinician at the practice
  • PRIMARY CARE PROVIDER: Provides oncology care
  • SURVIVOR: Evidence of a prior cancer (excluding non-melanoma skin cancer) within 3 years of the designated clinician visit

Participating Clinics

OptumCare Cancer Care at Charleston


2300 West Charleston Boulevard
Las Vegas, NV 89102
Map

702-384-0013

OptumCare Cancer Care at Seven Hills


3175 Saint Rose Parkway
Suite 200 Henderson, NV 89052
Map

702-384-0013
research@sncrf.org

OptumCare Cancer Care at Fort Apache


6190 South Fort Apache Road
Las Vegas, NV 89148
Map

702-384-0013
research@sncrf.org